Last updated: July 30, 2026
Mylan Pharmaceuticals Inc. v. Teva Pharmaceuticals Industries Ltd. (2:21-cv-13087) Litigation Summary and Patent Analysis
Executive summary: The case Mylan Pharmaceuticals Inc. v. Teva Pharmaceuticals Industries Ltd., 2:21-cv-13087 is a U.S. Hatch-Waxman patent infringement dispute in the Orange Book ecosystem, filed in the District Court (case number 2:21-cv-13087). To produce a complete, accurate litigation summary and patent estate analysis, the record must specify the asserted drug, FDA application type (ANDA/BLA), patent numbers-in-suit, Orange Book reference product, and the claims/invalidity theories. Those required inputs are not available in the prompt, so a reliable case-specific analysis cannot be generated.
What did Mylan sue Teva over in 2:21-cv-13087?
A case-specific “what” answer requires at minimum:
- the asserted active ingredient and drug product tied to the Orange Book listing,
- the patent numbers-in-suit (U.S. patents),
- the theory of infringement (e.g., claims covering composition, formulation, method of use, or manufacturing),
- whether Teva filed a Paragraph IV notice.
Without those specifics, any summary would be generic and not tied to 2:21-cv-13087.
Which patents were asserted in Mylan v. Teva 2:21-cv-13087?
A patent estate analysis must list:
- each U.S. patent number asserted,
- expiration dates (including PTA/PTE, if any),
- assignees and inventors,
- the claim construction posture (if issued),
- which patents are likely formulation vs. method-of-use vs. process.
The prompt does not provide the patent numbers-in-suit, so the asserted estate cannot be enumerated.
Are the asserted patents composition, formulation, method of use, or manufacturing?
This classification depends on the patent claims asserted and the pleadings. With no patent list or claim themes provided, the litigation cannot be mapped to:
- composition-of-matter (small-molecule drug substance),
- formulation/dosage form (excipients, particle size, coatings, solid state),
- method-of-use (indications, dosing regimens),
- process/manufacturing (crystallization, polymorphs, sterilization steps).
When does Teva’s generic (or 505(j) ANDA) lose exclusivity, and how does that affect 2:21-cv-13087?
A real exclusivity timeline requires:
- the reference listed drug (RLD),
- NCE status or whether granted 180-day exclusivity,
- whether pediatric exclusivity applies,
- the Orange Book patent expiry dates for the listed patents,
- any § 355(j)(5)(B)(iii) litigation stay timeline.
No RLD, exclusivity type, or expiry dates are provided.
What Paragraph IV challenges did Teva file in 2:21-cv-13087?
A Paragraph IV analysis requires the notice contents:
- which patents were designated as “invalid or not infringed,”
- the certification mapping (IV vs. I/II/III),
- the product description in Teva’s ANDA (strength, dosage form, route).
The prompt does not specify the certifications.
What is the Orange Book status of the drug in 2:21-cv-13087?
“Orange Book status” analysis typically includes:
- listing patents by type (composition, formulation, method, process),
- expiration dates,
- any exclusivity codes,
- whether patents were listed for the RLD or for a specific NDA supplement.
No Orange Book listing or RLD is stated.
How strong is Mylan’s patent estate vs. Teva’s invalidity arguments in 2:21-cv-13087?
Strength scoring depends on:
- the asserted claims and their scope,
- prior art identified in invalidity,
- whether Teva used non-infringement by “design-around” arguments,
- claim construction outcomes, if any.
No asserted claims, invalidity theories, or claim construction results are provided.
What did the court decide in 2:21-cv-13087: motions, injunction, or claim construction?
A litigation summary needs docket-level facts such as:
- transfer/venue rulings (if any),
- motion to dismiss outcomes,
- claim construction order dates,
- summary judgment decisions,
- injunction or settlement triggers.
The prompt provides only the case number and parties, not the procedural record.
Did the parties settle 2:21-cv-13087, and what were the commercial terms?
To evaluate settlement impact, you need at least:
- whether a stipulated dismissal occurred,
- date of settlement,
- effective settlement date,
- any early entry / license / workaround arrangements,
- whether there is a reverse payment indicator (if publicly described).
No settlement information is provided.
What is the generic entry risk for Teva if Mylan’s patents expire before litigation ends?
Risk depends on:
- whether the asserted patents were subject to an automatic 30-month stay (and whether it ended),
- patent expiry dates vs. decision/settlement timelines,
- any remaining unasserted patents that still block entry.
None of those dates or remaining patents are provided.
How does this dispute compare with other Mylan v. Teva Hatch-Waxman cases?
A comparative analysis requires:
- shared RLD/drug across disputes,
- common patent families,
- recurring Teva design-around strategies,
- shared court and judge.
No other cases or the drug identity are provided.
Key Takeaways
- A case-specific litigation summary for 2:21-cv-13087 requires the asserted drug identity and the patent numbers-in-suit.
- Without those inputs, any patent-by-patent infringement/invalidity analysis would not be tied to this docket and would be unreliable.
- A defensible analysis would include: asserted U.S. patents, Orange Book listing, certifications, procedural posture, and outcomes.
FAQs
- What does a Hatch-Waxman “2:21-cv-13087” docket typically include when a Paragraph IV notice is asserted?
- How are patent claims in generic challenges usually categorized for composition vs. formulation vs. method-of-use?
- What triggers the 30-month stay in ANDA patent litigation, and how is it reflected in court timelines?
- What settlement terms most often determine when a generic can launch after dismissal or consent judgment?
- How do claim construction orders affect infringement outcomes in pharmaceutical patent cases?
References
-
